A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00445471 |
Recruitment Status
:
Terminated
(Mifne began treating younger patients who could not be diagnosed with the ADOS used in the study)
First Posted
: March 9, 2007
Last Update Posted
: December 25, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Child Development Disorders, Pervasive | Behavioral: Mifne Approach to PDD Behavioral: Treatment as usual | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 45 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | April 2007 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |
Arm | Intervention/treatment |
---|---|
A
Mifne Approach to PDD
|
Behavioral: Mifne Approach to PDD |
B
Treatment as usual
|
Behavioral: Treatment as usual |
- ADOS scores at 3 and 6 months after commencement of treatment [ Time Frame: 2.5 years ]
- CGI-I score after 3 and 6 months [ Time Frame: 2.5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 5 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All children between the ages of 2-5 years who meet diagnostic criteria for Autism or Pervasive Developmental Disorder by DSM IV criteria who are referred for treatment at Mifne for the treatment group.
- The control group will consist of children meeting the same criteria who are referred to Schneider Children's Medical Center of Israel (SCMCI). Matching will be for age, sex, ethnicity, socioeconomic status, IQ, language development and diagnosis.
Exclusion criteria:
- All referred children who do not meet criteria for Autism or PDD or do not understand Hebrew.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00445471
Israel | |
Schneider Children's Medical Center of Israel, Departemnt of Psychological Medicine | |
Petach Tikva, Israel |
Principal Investigator: | Alan Apter, MD | Director Department of Psychological Medicine Schneider Children's Medical Center of Israel |
Responsible Party: | alan apter, Director, Feinberg Child Study Center and Department of Psychiatry, Schneider's Children's Medical Center of Israel, Rabin Medical Center |
ClinicalTrials.gov Identifier: | NCT00445471 History of Changes |
Other Study ID Numbers: |
4222 |
First Posted: | March 9, 2007 Key Record Dates |
Last Update Posted: | December 25, 2014 |
Last Verified: | December 2014 |
Keywords provided by alan apter, Rabin Medical Center:
Autism Spectrum Disorder Autistic Disorder Pervasive Developmental Disorder |
Additional relevant MeSH terms:
Developmental Disabilities Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders |